SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-117567
Filing Date
2024-10-28
Accepted
2024-10-28 06:59:35
Documents
13
Period of Report
2024-10-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K glue-20241025.htm   iXBRL 8-K 52305
2 EX-99.1 glue-ex99_1.htm EX-99.1 23950
3 GRAPHIC img106802192_0.jpg GRAPHIC 12665
  Complete submission text file 0000950170-24-117567.txt   225394

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT glue-20241025.xsd EX-101.SCH 30670
15 EXTRACTED XBRL INSTANCE DOCUMENT glue-20241025_htm.xml XML 4891
Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40522 | Film No.: 241398411
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)